These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33280474)

  • 41. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.
    Zhao J; Song Y; Liu D
    Biomark Res; 2019; 7():19. PubMed ID: 31528345
    [TBL] [Abstract][Full Text] [Related]  

  • 42. FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a
    Pulte ED; Norsworthy KJ; Wang Y; Xu Q; Qosa H; Gudi R; Przepiorka D; Fu W; Okusanya OO; Goldberg KB; De Claro RA; Farrell AT; Pazdur R
    Clin Cancer Res; 2021 Jul; 27(13):3515-3521. PubMed ID: 33632926
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The safety and efficacy of the re-administration of gilteritinib in a patient with FLT3-mutated R/R AML with CNS relapse: a case report.
    Ji Y; Wan Z; Yang J; Hao M; Liu L; Qin W
    Front Oncol; 2024; 14():1402970. PubMed ID: 39015500
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
    Antar AI; Otrock ZK; Jabbour E; Mohty M; Bazarbachi A
    Leukemia; 2020 Mar; 34(3):682-696. PubMed ID: 31919472
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments.
    Scholl S; Fleischmann M; Schnetzke U; Heidel FH
    Cells; 2020 Nov; 9(11):. PubMed ID: 33212779
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States.
    Wilson M; McDade C; Thiruvillakkat K; Rouse R; Sivamurthy K; Yan S
    J Manag Care Spec Pharm; 2024 Aug; 30(8):805-816. PubMed ID: 38625717
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.
    Hogan FL; Williams V; Knapper S
    Curr Cancer Drug Targets; 2020; 20(7):513-531. PubMed ID: 32418523
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of hypereosinophilia in a case of
    Martinez-Gutierrez LN; Burgher BC; Glynias MJ; Alvarado D; Griffiths EA; Glenn ST; Sung PJ
    Cold Spring Harb Mol Case Stud; 2023 Jun; 9(3):. PubMed ID: 37433680
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New drugs creating new challenges in acute myeloid leukemia.
    Tiong IS; Wei AH
    Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3-Mutated AML.
    Oncologist; 2021 Feb; 26 Suppl 1(Suppl 1):S10. PubMed ID: 33368797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.
    Kugler E; Cohen I; Amitai I; Ram R; Frisch A; Nachmias B; Canaani J; Moshe Y; Krayem B; Aumann S; Henig I; Vainstein V; Shargian L; Ganzel C; Yeshurun M; Levi I; Raanani P; Akria L; Ofran Y; Shimony S; Wolach O
    Br J Haematol; 2024 May; ():. PubMed ID: 38782575
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
    Roskoski R
    Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of gilteritinib in combination with chemotherapy in preclinical models of
    Ueno Y; Mori M; Kamiyama Y; Saito R; Kaneko N; Isshiki E; Kuromitsu S; Takeuchi M
    Oncotarget; 2019 Apr; 10(26):2530-2545. PubMed ID: 31069015
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Availability of FLT3 inhibitors: how do we use them?
    Perl AE
    Blood; 2019 Aug; 134(9):741-745. PubMed ID: 31243041
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia.
    Marjoncu D; Andrick B
    J Adv Pract Oncol; 2020; 11(1):104-108. PubMed ID: 33542854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gilteritinib administration in a hemodialysis patient.
    Tollkuci E; Tran T; Myers R
    J Oncol Pharm Pract; 2021 Jul; 27(5):1255-1257. PubMed ID: 33175659
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of Fms-like tyrosine kinase 3 (FLT3) ligand (FL) on antitumor activity of gilteritinib, a FLT3 inhibitor, in mice xenografted with FL-overexpressing cells.
    Kawase T; Nakazawa T; Eguchi T; Tsuzuki H; Ueno Y; Amano Y; Suzuki T; Mori M; Yoshida T
    Oncotarget; 2019 Oct; 10(58):6111-6123. PubMed ID: 31692922
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An Iridociliochoroidal Myeloid Sarcoma Associated With Relapsed Acute Myeloid Leukemia With FLT3-ITD Mutation, Treated With Gilteritinib, an FLT3 Inhibitor.
    Kim RS; Yaghy A; Wilde LR; Shields CL
    JAMA Ophthalmol; 2020 Apr; 138(4):418-419. PubMed ID: 32163103
    [No Abstract]   [Full Text] [Related]  

  • 60. Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.
    Dumas PY; Raffoux E; Bérard E; Bertoli S; Hospital MA; Heiblig M; Desbrosses Y; Bonmati C; Pautas C; Lambert J; Orvain C; Banos A; Pasquier F; Peterlin P; Marchand T; Uzunov M; Frayfer J; Turlure P; Cluzeau T; Jourdan E; Himberlin C; Tavernier E; Villate A; Haiat S; Chretien ML; Carre M; Chantepie S; Vaida I; Wemeau M; Chebrek S; Guillerm G; Guièze R; Debarri H; Gehlkopf E; Laribi K; Marcais A; Santagostino A; Béné MC; Mineur A; Pigneux A; Dombret H; Récher C
    Leukemia; 2023 Jan; 37(1):91-101. PubMed ID: 36376378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.